Hybrid trial leadership PCM Trials merged with EmVenio Research and Clinical Trials Service to form a comprehensive hybrid and decentralized clinical trial (DCT) solution. This presents a cross-sell opportunity to clients seeking end‑to‑end DCT capabilities, mobile nurse visits, and virtual site networks under one trusted provider.

Expansion credibility Recent acquisitions and leadership hires signal rapid growth and enhanced commercial credibility. The addition of a Chief Commercial Officer and a President, along with global expansion and a London office, create messaging for enterprise clients seeking scale, geographic reach, and robust project execution.

Global coverage With the Netherlands and US-based EmVenio platforms and plans for broader international reach, there is a clear pathway to target sponsors with multinational trials who require consistent mobile and virtual visit capabilities across regions.

Patient-centric focus Position the company as a leader in patient-centric, hybrid trial models. The emphasis on mobile visits and decentralized approaches aligns with sponsors prioritizing patient engagement, retention, and diverse site access to accelerate study timelines.

Technology stack leverage Utilize the tech stack including Salesforce, Sage Intacct, DocuSign and Azure/Teams to propose streamlined trial operations, centralized data management, eConsent, and scalable financial and contract workflows, appealing to sponsors seeking efficiency and compliance.